ES2068714T3 - Derivados de pirimidina para aumentar la actividad antitumoral. - Google Patents

Derivados de pirimidina para aumentar la actividad antitumoral.

Info

Publication number
ES2068714T3
ES2068714T3 ES92911036T ES92911036T ES2068714T3 ES 2068714 T3 ES2068714 T3 ES 2068714T3 ES 92911036 T ES92911036 T ES 92911036T ES 92911036 T ES92911036 T ES 92911036T ES 2068714 T3 ES2068714 T3 ES 2068714T3
Authority
ES
Spain
Prior art keywords
antitumoral activity
increase
derivatives
pirimidine derivatives
pirimidine
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
ES92911036T
Other languages
English (en)
Inventor
Jotham Wadsworth Coe
Anton Franz Josef Fliri
Takushi Kaneko
Eric Robert Larson
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
PFIZER
Pfizer Inc
Original Assignee
PFIZER
Pfizer Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by PFIZER, Pfizer Inc filed Critical PFIZER
Application granted granted Critical
Publication of ES2068714T3 publication Critical patent/ES2068714T3/es
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
    • C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
    • C07D239/28—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
    • C07D239/46—Two or more oxygen, sulphur or nitrogen atoms
    • C07D239/48—Two nitrogen atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Compositions Of Macromolecular Compounds (AREA)
  • Indole Compounds (AREA)

Abstract

DERIVADOS 2,4 GENTES QUIMIOTERAPEUTICOS EN EL TRATAMIENTO DE CANCER
ES92911036T 1991-04-17 1992-03-30 Derivados de pirimidina para aumentar la actividad antitumoral. Expired - Lifetime ES2068714T3 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US68689991A 1991-04-17 1991-04-17

Publications (1)

Publication Number Publication Date
ES2068714T3 true ES2068714T3 (es) 1995-04-16

Family

ID=24758194

Family Applications (1)

Application Number Title Priority Date Filing Date
ES92911036T Expired - Lifetime ES2068714T3 (es) 1991-04-17 1992-03-30 Derivados de pirimidina para aumentar la actividad antitumoral.

Country Status (22)

Country Link
EP (1) EP0580753B1 (es)
JP (1) JPH0819121B2 (es)
CN (1) CN1065863A (es)
AT (1) ATE119157T1 (es)
AU (1) AU653601B2 (es)
BR (1) BR9205906A (es)
CA (1) CA2108561A1 (es)
CZ (1) CZ390992A3 (es)
DE (2) DE69201559T2 (es)
DK (1) DK0580753T3 (es)
ES (1) ES2068714T3 (es)
FI (1) FI934565L (es)
GR (1) GR3015921T3 (es)
HU (1) HUT65177A (es)
IE (1) IE64915B1 (es)
MX (1) MX9201763A (es)
NO (1) NO933722D0 (es)
NZ (1) NZ242390A (es)
PT (1) PT100386A (es)
WO (1) WO1992018498A1 (es)
YU (1) YU39992A (es)
ZA (1) ZA922815B (es)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IN188411B (es) * 1997-03-27 2002-09-21 Yuhan Corp
US6440965B1 (en) 1997-10-15 2002-08-27 Krenitsky Pharmaceuticals, Inc. Substituted pyrimidine derivatives, their preparation and their use in the treatment of neurodegenerative or neurological disorders of the central nervous system
US7045519B2 (en) 1998-06-19 2006-05-16 Chiron Corporation Inhibitors of glycogen synthase kinase 3
KR100272471B1 (ko) 1998-11-17 2000-11-15 김선진 신규의 피리미딘 유도체 및 그의 제조방법
JP2003521468A (ja) 1999-03-17 2003-07-15 シグナル ファーマシューティカルズ， インコーポレイテッド エストロゲンレセプタを変調させるための化合物及び方法
US6593322B1 (en) 1999-03-17 2003-07-15 Signal Pharmaceuticals, Inc. Compounds and methods for modulation of estrogen receptors
US6583148B1 (en) 1999-04-08 2003-06-24 Krenitsky Pharmaceuticals, Inc. Neurotrophic substituted pyrimidines
US6630469B2 (en) 2000-05-09 2003-10-07 Bristol-Myers Squibb Company 5-HT7 receptor antagonists
JP5154728B2 (ja) 2000-07-24 2013-02-27 クレニツキー・ファーマシューティカルズ，インコーポレイテッド 神経栄養活性を有する置換５−アルキニルピリミジン
JP2005232081A (ja) * 2004-02-19 2005-09-02 Bayer Cropscience Ag ベンジルピリミジン誘導体の農園芸用殺菌剤としての利用
JP2010111702A (ja) 2009-02-16 2010-05-20 Tetsuya Nishio 複素環化合物、その製造法および用途
CN103333119A (zh) * 2013-05-28 2013-10-02 中国药科大学 1,2-二氢-6-甲基-4-取代氨基-5-嘧啶羧酸类化合物及其制备方法和用途
CN115232076A (zh) * 2022-07-25 2022-10-25 南通大学 苯氨基取代的嘧啶氨基酸衍生物及其制备方法与应用

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2744663B2 (ja) * 1988-12-29 1998-04-28 三井化学株式会社 ピリミジン類及びその薬学的に許容される塩類
HU206337B (en) * 1988-12-29 1992-10-28 Mitsui Petrochemical Ind Process for producing pyrimidine derivatives and pharmaceutical compositions

Also Published As

Publication number Publication date
FI934565A7 (fi) 1993-10-15
NZ242390A (en) 1994-09-27
PT100386A (pt) 1993-06-30
DE9290039U1 (de) 1993-12-09
FI934565A0 (fi) 1993-10-15
JPH0819121B2 (ja) 1996-02-28
IE64915B1 (en) 1995-09-20
HU9302929D0 (en) 1993-12-28
CZ390992A3 (en) 1994-03-16
ZA922815B (en) 1993-10-18
EP0580753A1 (en) 1994-02-02
EP0580753B1 (en) 1995-03-01
DE69201559D1 (de) 1995-04-06
GR3015921T3 (en) 1995-07-31
NO933722L (no) 1993-10-15
MX9201763A (es) 1992-10-01
AU653601B2 (en) 1994-10-06
AU1776192A (en) 1992-11-17
NO933722D0 (no) 1993-10-15
WO1992018498A1 (en) 1992-10-29
DE69201559T2 (de) 1995-07-13
DK0580753T3 (da) 1995-07-03
HUT65177A (en) 1994-05-02
BR9205906A (pt) 1994-07-05
CA2108561A1 (en) 1992-10-18
YU39992A (sh) 1995-01-31
CN1065863A (zh) 1992-11-04
JPH06501023A (ja) 1994-01-27
FI934565L (fi) 1993-10-15
IE921214A1 (en) 1992-10-21
ATE119157T1 (de) 1995-03-15

Similar Documents

Publication Publication Date Title
ES2071484T3 (es) Derivados de 2,4-diaminoquinazolinas para aumentar la actividad antitumoral.
MX9101913A (es) Derivados de quinazolinas para potenciar la actividad antitumoral
DK0574457T3 (da) Antiviral nucleosidkombination
MX9400434A (es) Potenciamiento de temozolomida en celulas de tumores humanos.
ES2179096T3 (es) Utilizacion de la interleucina-12 para prevenir la reaccion del injerto contra el huesped.
ES2153862T3 (es) Bisulfan de administracion parenteral para el tratamiento de enfermedades malignas.
PL323798A1 (en) Application of derivatives of vitamin d4 in treating skin diseases
MX9701385A (es) Preparacion de producto combinado para usarse en enfermedades inmunologicas.
ES2063202T3 (es) Nuevas 5,11-dihidro-6h-dipirido(3,2-b:2',3'-e)(1,4)diazepin-6-onas y -tionas y su uso en la prevencion o tratamiento del sida.
IT1264530B (it) Impiego dei polisaccaridi nelle neuropatie atrofico degenerative
DK0520200T3 (da) Imadazol-forbindelser, deres fremstilling og anvendelse
MX9201763A (es) Derivados de pirimidina para aumentar la actividad antitumores.
NO890046L (no) Disubstituerte pyridiner.
NO970178L (no) Terpenoidderivater (sarcodictyiner) som er nyttige som antitumormidler
ES2066096T3 (es) 4-bencil-5-fenil-2,4-dihidro-3h-1,2,4-triazol-3-onas y su uso como anticonvulsivos.
ES2069758T3 (es) Uso de buspirona en apneas del sueño.
IL131478A0 (en) Methods for treatment of scar tissue
ES2076141T3 (es) 5-aril-3h-1,2,4-triazol-3-onas y su uso como anticonvulsivos.
ES2058349T3 (es) Utilizacion de betabloqueadores para el tratamiento de la progresion de la miopia axial infantil.
ITMI912466A1 (it) Uso di 1, 2 dipalmitoil-l-alfa-fosfatidil-n, n-dimetiletanolammina, in composizioni dermatologiche
ZA893310B (en) Novel strobilurine derivatives,their preparation and their use
IT8619457A0 (it) Derivati insaturi cicloalifatici, loro procedimenti di prepatazione e loro impiego in terapia e in cosmetica.
DE69106720D1 (de) Mentholderivate mit spasmolytik aktivität.
FI972637A0 (fi) K-ryhmän vitamiinin käyttö lisäkilpirauhasen liikatoiminnan hoitoon
FI913531A0 (fi) Anvaendning av 1,2-bensopyronderivater till behandling av maligna tumoerer hos maenniskan.

Legal Events

Date Code Title Description
FG2A Definitive protection

Ref document number: 580753

Country of ref document: ES